PrescriptionDrugs.org

What to Expect When Starting Buspirone

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Buspirone is an anxiolytic medication used to treat generalized anxiety disorder (GAD). Unlike benzodiazepines (Xanax, Valium), buspirone is not habit-forming, does not cause sedation, and does not work immediately — it must be taken consistently for 2-4 weeks before anxiety relief becomes apparent. It is a preferred option for patients who cannot take benzodiazepines or need long-term anxiety management.

Week-by-week timeline

Week 1

Starting Buspirone

Buspirone is typically started at 7.5 mg twice daily and may be increased gradually. Common early side effects include dizziness, nausea, headache, and a feeling of nervousness or restlessness (often transient). Take doses consistently and with food to reduce nausea. Do not expect immediate anxiety relief — this is not a fast-acting medication.

Week 2

Side Effects Adjusting

Early side effects often improve in the second week as your body adjusts. Dizziness is most common in the first 1-2 weeks and typically resolves. The dose may be increased toward the target range (15-30 mg/day in divided doses, maximum 60 mg/day).

Week 3-4

Emerging Therapeutic Effects

Most patients begin to notice reduced anxiety, improved ability to cope with stress, and less physical anxiety symptoms (heart racing, muscle tension) in weeks 3-4. The effect is subtle and gradual — buspirone does not produce the rapid calm of a benzodiazepine.

Month 1-2

Full Therapeutic Assessment

Full anxiolytic effects are typically achieved at 4-6 weeks at the target dose. Reassess with your prescriber: Is anxiety meaningfully better? Are side effects manageable? If response is insufficient, the dose may be increased.

Month 2-3

Long-Term Anxiety Management

Buspirone is safe for long-term use and does not cause tolerance or dependence. It works best combined with therapy (CBT) for anxiety disorders. Unlike benzodiazepines, stopping buspirone does not cause withdrawal — it can be stopped gradually without taper if needed.

When to call your doctor

Contact your healthcare provider if you experience:

  • Severe dizziness or fainting
  • Chest pain or irregular heartbeat
  • Severe depression or thoughts of self-harm
  • Signs of serotonin syndrome if combined with other serotonergic medications: agitation, confusion, rapid heart rate, fever, muscle twitching
  • Significant worsening of anxiety after 4+ weeks at therapeutic dose
  • Unusual movements or muscle stiffness (rare movement side effects)

Tips for getting started

Buspirone requires consistent twice-daily dosing to work — do not skip doses or take only as-needed. It can be taken with or without food, but choose one way and stick with it consistently (food affects absorption). Give it a full 4-6 weeks before judging effectiveness. Avoid grapefruit juice, which increases buspirone levels. Buspirone does not prevent panic attacks and is not a benzodiazepine — if you are switching from a benzodiazepine, the benzo must be tapered gradually (buspirone does not substitute for benzodiazepine withdrawal management).

Frequently asked questions

More about Buspirone

References

  1. [Regulatory] FDA Label: Buspirone Hydrochloride Tablets https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf Accessed 2026-03-01.
  2. [Regulatory] NIH MedlinePlus: Buspirone https://medlineplus.gov/druginfo/meds/a688005.html Accessed 2026-03-01.
  3. [Regulatory] NICE Guidelines: Generalized Anxiety Disorder Treatment https://www.nice.org.uk/guidance/cg113 Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: